Tharimmune makes a pivot into digital assets, raises approximately $540 million via a private placement
By Cryptopolitan
Tharimmune, Inc., a clinical-stage biotechnology company traditionally focused on developing therapies for rare immune, inflammatory, and oncologic diseases, has just announced its pivot into digital assets, raising approximately $540 million via a private placement led by proprietary trading firm DRW and crypto-focused venture capital firm Liberty City Ventures. According to Tharimmune, Inc.
Article Details
Tharimmune, Inc., a clinical-stage biotechnology company traditionally focused on developing therapies for rare immune, inflammatory, and oncologic diseases, has just announced its pivot into digital assets, raising approximately $540 million via a private placement led by proprietary trading firm DRW and crypto-focused venture capital firm Liberty City Ventures. According to Tharimmune, Inc.
